Jun 30, 2008 by Brian Orelli, PhDMerck and Schering Get Half a DivorceThe lovey-dovey duo ends their respiratory partnership.
Jun 27, 2008 by Brian Orelli, PhDBarr's Lawyers Earn Their KeepThe generic-drug company gets another patent thrown out.
Jun 27, 2008 by Brian Orelli, PhDThe Right Time to Raise Capital Sequenom's management grabs some cash after its stock price doubles.
Jun 26, 2008 by Brian Orelli, PhDWhy Throw Tomatoes at Monsanto?With valuations high, investors are jittery.
Jun 26, 2008 by Brian Orelli, PhDThe FDA's Latest VictimMerck fails to get its Gardasil vaccine approved to treat older women.
Jun 25, 2008 by Brian Orelli, PhDWuXi's Shortsighted DealWuXi partners with Covance, but is it really a good long-term play?
Jun 25, 2008 by Brian Orelli, PhDAn Even More Complicated Patent SettlementBarr and Bayer settle their dispute about Yasmin. That's as simple as it gets.
Jun 25, 2008 by Brian Orelli, PhDFactory-Farming Friendliness Bugs MeSyngenta and DuPont join forces for a insect-killing tech swap.
Jun 23, 2008 by Brian Orelli, PhDFDA Sets a Higher Standard for MerckImproved cholesterol levels aren't a good enough goal for these drugs.
Jun 20, 2008 by Brian Orelli, PhDLive From Bio: Personalized MedicineThe movement is chugging along thanks to diagnostics.
Jun 19, 2008 by Brian Orelli, PhDLive From Bio: Activist Investors When activist investors board your company's ship.
Jun 19, 2008 by Brian Orelli, PhDLive From Bio: Investing in Orphan DrugsThere's money to be made in selling drugs to just a few people.
Jun 17, 2008 by Brian Orelli, PhDAcadia Gets HalvedDrug fails, stock goes down. Welcome to drug development.
Jun 17, 2008 by Brian Orelli, PhDChange a Label, Change the GameTeva's Parkinson's drug does more than treat symptoms.
Jun 16, 2008 by Brian Orelli, PhDMore Cancer Issues for Johnson & JohnsonDefinitely not a good side effect profile to have.
Jun 13, 2008 by Brian Orelli, PhDHigh-Tech Health-Care Stocks to Keep Dad HealthyGrow older, stay healthy, make money.
Jun 13, 2008 by Brian Orelli, PhDSome Insight Into Incyte's DataA rheumatoid arthritis drug looks promising, according to early numbers.
Jun 12, 2008 by Brian Orelli, PhDSchering-Plough and J&J Score a Triple-TripleThree phase 3 trials for a single drug? Oh my.
